Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics reports promising interim results from its Phase 2 trial of ATH434, indicating potential benefits for patients with Multiple System Atrophy (MSA). The company’s bioMUSE Natural History Study has been instrumental in shaping the trial’s approach and endpoints. With a solid cash position of A$12.6 million as of June 30, 2024, Alterity continues to make significant progress in neurodegenerative disease research.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
